On Wednesday, February 11, 2015 Rite Aid agreed to the purchase of top pharmacy benefit manager, Envision Pharmaceutical Services for roughly $2 Billion in cash and stock. Below are some reactions to the transaction:
- The market has reacted favorably to Rite Aid's purchase. The company's stock is up about 10% today (above $8). This is a far cry from when Rite Aid's stock was trading at $.22 per share.
- It is amazing that Rite Aid made such a large acquisition primarily from cash.
- The acquisition is predicted to add about $5 billion dollars to Rite Aid's sales. The transactions is a strong add to top line growth and accretive to Rite Aid this year.
- Rite Aid (Rated B2 by Moody's) is just catching up with CVS and Walgreens that have previously acquired benefits managers but it is a welcome addition.
- With regard to net lease investment sales, Rite Aid cap rates have dramatically compressed in the last two years and Rite Aid properties with longer term leases are now being offered in the low 6's.
- On the negative side, Rite Aid is still developing a small number of new stores per year so there aren't very many Rite Aids on the market.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.